Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23-08:00November 14th, 2016|2016 Press Releases, Press Releases| Read more
Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic LeukemiaInvivoscribe Marketing2021-02-12T18:36:01-08:00October 31st, 2016|2016 Publications, Featured Publications, Publications| Read more
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30-08:00May 31st, 2016|2016 Press Releases, Press Releases| Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37-08:00March 28th, 2016|2016 Press Releases, Press Releases| Read more
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49-08:00February 18th, 2016|2016 Press Releases, Press Releases| Read more
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientificwmm2021-02-26T19:15:19-08:00February 9th, 2016|2016 Press Releases, Press Releases| Read more
Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinicopathological Variants with Different OutcomesInvivoscribe Marketing2021-02-12T22:19:56-08:00February 1st, 2016|2016 Publications, Publications| Read more